Breast Cancer Research and Treatment

, Volume 113, Issue 3, pp 501–507

HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer

  • Julie E. Lang
  • Kailash Mosalpuria
  • Massimo Cristofanilli
  • Savitri Krishnamurthy
  • James Reuben
  • Balraj Singh
  • Isabelle Bedrosian
  • Funda Meric-Bernstam
  • Anthony Lucci
Clinical Trial

Abstract

Introduction Circulating tumor cells (CTCs) correlate with worse prognosis in patients with metastatic breast cancer, but there are little data on CTCs in operable patients. We hypothesized that primary tumor characteristics would predict the likelihood of identifying CTCs in patients with operable breast cancer. Methods Clinical and pathological data from 92 patients with operable breast cancer were collected. The CellSearch system was used to detect CTCs in 30 ml of peripheral blood. CTCs were defined as nucleated cells lacking CD45 but expressing cytokeratins 8, 18, or 19. Univariate analysis was performed to determine if the presence of any primary tumor characteristic was predictive of CTCs. As a secondary objective we evaluated if nodal or bone marrow status was predictive of CTCs. Results Thirty-eight percent of patients (35/92) had evidence of CTCs, with a median number of 1.0 CTC per CTC positive patient (range 1–22). HER2 status was the sole primary tumor characteristic that reliably predicted the presence of CTCs (P = 0.01, risk ratio = 3.66). No significant association was found between the presence of CTCs and tumor size (T), estrogen receptor (ER) status, progesterone receptor (PR) status, grade, histologic type, degree of nodal involvement (N), lymphovascular invasion (LVI) or Ki-67 proliferation. Bone marrow micrometastases were found in 17/64 (26.6%) of the patients but did not correlate with the presence of CTCs. Conclusion HER2 status was the only primary tumor characteristic that correlated with the presence of CTCs. Long-term follow-up will be required to determine the significance of CTCs in operable breast cancer.

Keywords

Circulating tumor cells Breast cancer Micrometastases Minimal residual disease CTC 

References

  1. 1.
    Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802PubMedCrossRefGoogle Scholar
  2. 2.
    Lang JE, Hall CS, Singh B et al (2007) Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther 7:1463–1472PubMedCrossRefGoogle Scholar
  3. 3.
    Wulfing P, Borchard J, Buerger H et al (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12:1715–1720PubMedCrossRefGoogle Scholar
  4. 4.
    Pierga JY, Bonneton C, Vincent-Salomon A et al (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clinical Cancer Research 10:1392–1400PubMedCrossRefGoogle Scholar
  5. 5.
    Meng S, Tripathy D, Shete S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101:9393–9398PubMedCrossRefGoogle Scholar
  6. 6.
    Xenidis N, Perraki M, Kafousi M et al (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24:3756–3762PubMedCrossRefGoogle Scholar
  7. 7.
    Zach O, Kasparu H, Wagner H et al (2002) Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med Austriaca Suppl 59:32–34PubMedGoogle Scholar
  8. 8.
    Gaforio JJ, Serrano MJ, Sanchez-Rovira P et al (2003) Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 107:984–990PubMedCrossRefGoogle Scholar
  9. 9.
    Stathopoulos EN, Sanidas E, Kafousi M et al (2005) Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 16:240–246PubMedCrossRefGoogle Scholar
  10. 10.
    Benoy IH, Elst H, Philips M et al (2006) Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94:672–680PubMedGoogle Scholar
  11. 11.
    Naume B, Borgen E, Beiske K et al (1997) Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6:103–114PubMedGoogle Scholar
  12. 12.
    Racila E, Euhus D, Weiss AJ et al (1998) Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 95:4589–4594PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou L, Wang K, Tan W et al (2006) Quantitative intracellular molecular profiling using a one-dimensional flow system. Analytical chemistry 78:6246–6251PubMedCrossRefGoogle Scholar
  14. 14.
    Ring A, Smith IE, Dowsett M (2004) Circulating tumour cells in breast cancer. Lancet Oncol 5:79–88PubMedCrossRefGoogle Scholar
  15. 15.
    Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791PubMedCrossRefGoogle Scholar
  16. 16.
    Tibbe AG, Miller MC, Terstappen LW (2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71:154–162PubMedGoogle Scholar
  17. 17.
    Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904PubMedCrossRefGoogle Scholar
  18. 18.
    Riethdorf S, Fritsche H, Muller V et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13:920–928PubMedCrossRefGoogle Scholar
  19. 19.
    Rack B, Schindlbeck C, Janni W et al (2006) Incidence of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients at primary diagnosis—a potential tool for risk stratification, ASCO Annual Meeting (J Clin Oncol (ed) (2006) 2006 ASCO Annual Meeting Proceedings Part I 24(18S: June 20 Supplement):20053)Google Scholar
  20. 20.
    Rack B, Schindlbeck C, Hofmann S et al (2007) Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients, ASCO Annual Meeting. J Clin Oncol (2007) 2007 ASCO Annual Meeting Proceedings Part I 25(18S: June 20 Supplement):10595Google Scholar
  21. 21.
    Nimeus-Malmstrom E, Ritz C, Eden P et al (2006) Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 42:2729–2737PubMedCrossRefGoogle Scholar
  22. 22.
    Pantel K, Schlimok G, Braun S et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424PubMedCrossRefGoogle Scholar
  23. 23.
    Smith I, Procter M, D Gelber R et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRefGoogle Scholar
  24. 24.
    Alvarado M, Brissaud C, Scott J et al (2007) Disseminated tumor cells correlate with estrogen receptor positivity in operable breast cancer patients. San Antonio Breast Cancer SymposiumGoogle Scholar
  25. 25.
    Meng S, Tripathy D, Shete S et al (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103:17361–17365PubMedCrossRefGoogle Scholar
  26. 26.
    Ignatiadis M, Xenidis N, Perraki M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202PubMedCrossRefGoogle Scholar
  27. 27.
    Hayes DF, Walker TM, Singh B et al (2002) Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 21:1111–1117PubMedGoogle Scholar
  28. 28.
    McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184PubMedCrossRefGoogle Scholar
  29. 29.
    Cristofanilli M, Broglio KR, Guarneri V et al (2007) Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 7:471–479PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Julie E. Lang
    • 1
  • Kailash Mosalpuria
    • 1
  • Massimo Cristofanilli
    • 2
  • Savitri Krishnamurthy
    • 3
  • James Reuben
    • 3
  • Balraj Singh
    • 1
  • Isabelle Bedrosian
    • 1
  • Funda Meric-Bernstam
    • 1
  • Anthony Lucci
    • 1
  1. 1.Department of Surgical Oncology, MD Anderson Cancer Center, Advanced Research Center for Microscopic Disease (ARC-MD)The University of TexasHoustonUSA
  2. 2.Department of Medical Oncology, MD Anderson Cancer Center, Advanced Research Center for Microscopic Disease (ARC-MD)The University of TexasHoustonUSA
  3. 3.Department of Pathology, MD Anderson Cancer Center, Advanced Research Center for Microscopic Disease (ARC-MD)The University of TexasHoustonUSA

Personalised recommendations